# Hydroxychloroquine for Thrombosis Prevention and Antiphospholipid Antibody Reduction in Primary Antiphospholipid Syndrome

> **NCT04153201** · NA · COMPLETED · sponsor: **National and Kapodistrian University of Athens** · enrollment: 50 (actual)

## Conditions studied

- Antiphospholipid Syndrome

## Interventions

- **DRUG:** Hydroxychloroquine

## Key facts

- **NCT ID:** NCT04153201
- **Lead sponsor:** National and Kapodistrian University of Athens
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-15
- **Primary completion:** 2019-10-01
- **Final completion:** 2019-10-16
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2019-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04153201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04153201, "Hydroxychloroquine for Thrombosis Prevention and Antiphospholipid Antibody Reduction in Primary Antiphospholipid Syndrome". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04153201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*